VITRIFICATION FOR TISSUE ENGINEERED BLOOD VESSELS

组织工程血管的玻璃化

• 批准号: 6292599
• 负责人: Ying Song
• 金额: $ 10万
• 依托单位: ORGAN RECOVERY SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-04-01 至 2002-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6292599
• 关键词: amorphous solid; biomechanics; biotechnology; blood vessel prosthesis; blood vessels; cryopreservation; cytoprotection; physiology; technology /technique development; tissue engineering

DESCRIPTION (Verbatim From Applicant's Abstract): Effective methods of preservation are irnportant for the remerging technology of tissue engineering. We recently demonstrated, for the first time, that vitrification can have a salutary effect on the cryopreservation of a complete tissue, rabbit jugular vein, which otherwise sustains significant injury from freezing. Restriction of the amount and size of ice crystal formation during cryopreservation can be achieved by promotion of amorphous solidification (vitrification) rather than crystallization In this Phase I SBIR proposal, the primary objective is to test the feasibility of employing vitrification for long-term storage of tissue engineered blood vessels (TEBV). The effects of vitrification and conventional cryopreservation involving ice formation will be assessed using biomechanical tests, cell viability assays and vascular physiology methods. If vitrification is shown to be feasible for storage of TEBVs, these studies will be extended to a Phase II SBIR proposal to include in vivo testing of the Duke University TEBVs and TEBVs being developed by other organizations. PROPOSED COMMERCIAL APPLICATION: Customers are tissue engineering, tissue processing and banking organizations, and companies supplying reagents and biological materials to research organizations. The tissue engineering industry addresses diseases and disorders associated with over $500 billion expended annually in the U.S. for health care costs.

描述（逐字摘自申请人的摘要）：有效的方法 保存对于组织工程的再生技术具有重要意义。 我们最近首次证明玻璃化可以具有 对完整组织兔颈静脉冷冻保存的有益作用 静脉，否则会因冷冻而遭受严重损伤。限制 冷冻保存过程中冰晶形成的数量和大小可以 通过促进非晶态凝固（玻璃化）而不是 结晶 在第一阶段 SBIR 提案中，主要目标是测试 采用玻璃化技术长期保存组织的可行性 工程血管（TEBV）。玻璃化和常规的效果 涉及冰形成的冷冻保存将使用生物力学进行评估 测试、细胞活力测定和血管生理学方法。如果玻璃化 被证明对于 TEBV 的存储是可行的，这些研究将扩展到 II 期 SBIR 提案包括杜克大学的体内测试 TEBV 和其他组织正在开发的 TEBV。 拟议的商业应用： 客户包括组织工程、组织加工和银行机构，以及 向研究组织提供试剂和生物材料的公司。 这 组织工程行业解决与过度相关的疾病和病症 美国每年花费 5000 亿美元用于医疗保健费用。

项目成果

Vitrification of tissue engineered pancreatic substitute.

组织工程胰腺替代品的玻璃化冷冻。

• DOI: 10.1016/j.transproceed.2004.11.027
• 发表时间: 2005
• 期刊: Transplantation proceedings.
• 作者: Song,YC;Chen,ZZ;Mukherjee,N;Lightfoot,FG;Taylor,MJ;Brockbank,KG;Sambanis,A
• 通讯作者: Sambanis,A